<SEC-DOCUMENT>0001393905-24-000417.txt : 20241211
<SEC-HEADER>0001393905-24-000417.hdr.sgml : 20241211
<ACCEPTANCE-DATETIME>20241211141736
ACCESSION NUMBER:		0001393905-24-000417
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20241211
FILED AS OF DATE:		20241211
DATE AS OF CHANGE:		20241211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOHARVEST SCIENCES INC.
		CENTRAL INDEX KEY:			0001723464
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42389
		FILM NUMBER:		241541192

	BUSINESS ADDRESS:	
		STREET 1:		1140 - 625 HOWE STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C 2T6
		BUSINESS PHONE:		6046221186

	MAIL ADDRESS:	
		STREET 1:		1140 - 625 HOWE STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C 2T6

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CANNA-V-CELL SCIENCES INC.
		DATE OF NAME CHANGE:	20191008

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Midnight Star Ventures Corp.
		DATE OF NAME CHANGE:	20171121
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>bhsc_6k.htm
<DESCRIPTION>REPORT
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXC4Y912124VE8AL0SZ]. www.edgarsuite.com -->
<HEAD>
<TITLE>Report</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><TABLE align=center style='border-collapse:collapse;width:100%;border-bottom:1.5pt solid #000000'><TR><TD valign=top style=width:467.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>UNITED STATES</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>WASHINGTON, DC 20549</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:14pt Times New Roman;margin:0'><B>FORM 6-K</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>For the month of <B>December 2024</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>Commission file number: <B>000-56663</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:16pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Exact name of Registrant as specified in its charter)</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Not applicable</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Translation of Registrant&#8217;s name into English)</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Address of principal executive offices)</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style='font-family:Segoe UI Symbol'>&#9746;</FONT> Form 20-F&nbsp;&#9744; Form 40-F</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT style='font-family:Segoe UI Symbol'>&#9744;</FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT style='font-family:Segoe UI Symbol'>&#9744;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style='border-collapse:collapse;width:100%;border-bottom:1.5pt solid #000000'><TR><TD valign=top style=width:468pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><A name=_PART_III /><A name=_ITEM_19._EXHIBITS /><B>SUBMITTED HEREWITH</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Exhibits:</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=bottom style=width:71.85pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'><B>Exhibit</B></P>
</TD><TD valign=bottom style=width:396.15pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'><B>Description</B></P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#DBE5F1 style=width:71.85pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'><FONT style='color:#215E99;border-bottom:1px solid #215E99'><A href=bhsc_ex991.htm style=text-decoration:none>99.1</A></FONT></P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:396.15pt;padding-left:5.4pt;padding-right:5.4pt><P align=justify style='font:10pt Times New Roman;margin:0'>News Release dated December 11, 2024</P>
</TD></TR>
</TABLE>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><A name=_SIGNATURES /><A name=_Toc169189235 /><A name=_Toc172699253 /><B>SIGNATURES</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse><TR><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
</TD></TR>
<TR><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>(Registrant)</P>
</TD></TR>
<TR><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>Date: December 11, 2024</P>
</TD><TD valign=top style='width:233.75pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><I>/s/ David Ryan</I></P>
</TD></TR>
<TR><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:233.75pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Name: David Ryan</P>
</TD></TR>
<TR><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>Title: Vice-President, Investor Relations &amp; Secretary</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'> &nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>bhsc_ex991.htm
<DESCRIPTION>PRESS RELEASE DATED DECEMBER 11, 2024
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXC4Y912124VE8AL0SZ]. www.edgarsuite.com -->
<HEAD>
<TITLE>Press Release dated December 11, 2024</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=center style='font:9pt Times New Roman;margin:0'><FONT style=font-size:10pt><IMG src=bhscex991_1.jpg width=291 height=103 alt='Picture 5' title='Picture 5'><B>____________________________________________________________________________</B></FONT></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:14pt Times New Roman;margin:0'><B>Tate &amp; Lyle and BioHarvest Announce Partnership to Drive the Future of</B></P>
<P align=center style='font:14pt Times New Roman;margin:0'><B>Ingredients through Botanical Synthesis Technology</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&#8239;</P>
<P align=center style='font:12pt Times New Roman;margin:0'><I>New collaboration to pioneer next generation of</I></P>
<P align=center style='font:12pt Times New Roman;margin:0'><I>plant-based ingredients for healthier food and beverages</I></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&#8239;&#8239;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>December 11, 2024 - London, UK and Vancouver, Canada -</B> Tate &amp; Lyle PLC (&#8216;Tate &amp; Lyle&#8217;), a world leader in ingredient solutions for healthier and tastier food and beverages, and BioHarvest Sciences (NASDAQ:BHST) (CSE:BHSC) (&#8216;BioHarvest&#8217;), leaders in Botanical Synthesis, announce a pioneering new partnership to develop the next-generation of proprietary plant-based molecules to address increasing consumer desire for affordable, nutritious and more sustainable plant-derived food and beverage ingredients.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>BioHarvest&#8217;s proven Botanical Synthesis platform produces non-GMO plant-derived ingredients in a more sustainable and economically viable way, helping to scale up the production of highly beneficial botanical ingredients. This proprietary process delivers patentable molecules by growing targeted plant cells which can mirror and magnify the phyto-nutrients contained in specific plants, delivering all the benefits of the plant, without having to grow the plant.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The new partnership between Tate &amp; Lyle and BioHarvest will focus on developing the next generation of sweeteners - botanical sweetening ingredients using plant-derived molecules. Along with the BioHarvest proprietary platform, this will meet consumer desire for a sugar-like taste - with no after-taste - and enable a wider population to have more choice when it comes to accessing healthier ingredients in products. &nbsp;The ingredient solutions will be more affordable to the food and beverage industry while using a fraction of the land and water required in traditional extraction and land-based growing practices.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Tate &amp; Lyle brings its broad portfolio of sugar reduction solutions and years of ingredient research to the partnership, as well as its applications, nutrition and regulatory expertise, and access to global customers. The partnership forms part of Tate &amp; Lyle&#8217;s ongoing open innovation programme.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Nick Hampton, Chief Executive, Tate &amp; Lyle commented:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&#8220;We are always looking to provide our customers with the latest innovation in the marketplace - this partnership with BioHarvest allows us to do just that.&#8239; Our open innovation programme is all about creating cutting-edge solutions for the food and beverage industry. By partnering with entrepreneurial innovators like BioHarvest, we aim to disrupt the future of food for the better.&#8221;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Victoria Spadaro-Grant, Tate &amp; Lyle&#8217;s Chief Science and Innovation Officer said:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&#8220;This partnership is very exciting for Tate &amp; Lyle. BioHarvest provides the first and only fully validated industrial scale plant cell technology platform for production of plant metabolites. Initial exploration will focus on our sweetener platform, but our partnership also provides for expansion into other areas.&#8221;</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:8pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Ilan Sobel, CEO of BioHarvest Sciences said:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&#8220;We aspire to improve human wellness by availing our plant derived molecules to hundreds of millions of people and Tate &amp; Lyle represents an ideal partner.&#8239;Tate &amp; Lyle is a global powerhouse in food ingredient innovation, and we expect that its regulatory and nutrition expertise, industry knowledge and complementary research initiatives will help expedite and commercialise the next generation of plant-based molecules developed through our Botanical Synthesis platform.&#8221;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Dr Yochi Hagay, CTO and Co-Founder of BioHarvest Sciences added:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&#8220;This partnership forms a major milestone in the history of BioHarvest Sciences. It follows more than 15 years of intensive R&amp;D and manufacturing scaling of our Botanical Synthesis technology process to the point that global innovators like Tate &amp; Lyle can now leverage our capabilities to develop new plant-derived molecules to better meet consumer demand for healthier food and beverages.&#8221;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>About Tate &amp; Lyle PLC:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Supported by our 165-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients and solutions every day.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Through our leading expertise in sweetening, mouthfeel and forti&#64257;cation, we develop ingredients and solutions which reduce sugar, calories and fat, add &#64257;bre and protein, and provide texture and stability to food and drink in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Tate &amp; Lyle recently acquired CP Kelco, a leading provider of pectin, speciality gums and other nature-based ingredients to create a leader in mouthfeel, significantly enhancing our solutions capabilities. Following this combination, we now have more than 5,000 employees working in around 75 locations in 39 countries, serving customers in more than 120 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives through the Science of Food. By living our purpose, we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet. Tate &amp; Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. For the year ended 31 March 2024, and on a pro forma basis which assumes for illustrative purposes that the combination with CP Kelco took place on 1 April 2023, revenue for the enlarged Tate &amp; Lyle Group would have been &#163;2.25 billion. For more information, please visit <FONT style='color:#0070C0;border-bottom:1px solid #0070C0'>www.tateandlyle.com</FONT> or follow Tate &amp; Lyle on <FONT style='color:#0070C0;border-bottom:1px solid #0070C0'>LinkedIn</FONT>, <FONT style='color:#0070C0;border-bottom:1px solid #0070C0'>X (Twitter)</FONT>, <FONT style='color:#0070C0;border-bottom:1px solid #0070C0'>Facebook</FONT> or <FONT style='color:#0070C0;border-bottom:1px solid #0070C0'>YouTube</FONT>.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>About BioHarvest Sciences Inc:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>BioHarvest Sciences Inc. (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV) is a leader in bioscience, leveraging its patented Botanical Synthesis technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its Botanical Synthesis process technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit <FONT style='color:#0070C0;border-bottom:1px solid #0070C0'>www.bioharvest.com</FONT>.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Forward-Looking Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Information set forth in this news release might include forward-looking statements that are based on management&#8217;s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. &nbsp;There is no assurance that new sweetener molecules will be commercialized, as any </P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>formulations will need to be tested for product suitability, which will include factors such as taste, after-taste, and affordability. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For media enquiries, contact:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Maxine Boersma, Snr Manager, Global Corporate PR, Tate &amp; Lyle PLC</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><FONT style='color:#0070C0;border-bottom:1px solid #0070C0'>Maxine.Boersma@tateandlyle.com</FONT>&#8239;+44(0) 7502 919579</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>BioHarvest Corporate Contact:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Dave Ryan, VP Investor Relations</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>+1 (604) 622-1186</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><FONT style='color:#0070C0;border-bottom:1px solid #0070C0'>info@bioharvest.com</FONT></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Investor Relations Contact:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Lucas A. Zimmerman</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Managing Director</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>MZ Group - MZ North America</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>+1 (949) 259-4987</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><FONT style='color:#0070C0;border-bottom:1px solid #0070C0'>BHSC@mzgroup.us</FONT></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>bhscex991_1.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 bhscex991_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !K 2X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO-O@-KM[K'C
MKXLPW5U/<1:=XO6VM$D?<+:+^R=-DV)Z+OD=L>KGUH ])HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KRS]G7_ )*%\9?^QV7_ -,VE5ZG7EG[.O\ R4+X
MR_\ 8[+_ .F;2J /4Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M  P_Z'[PG_X,HO\ &MCXU?&G0/@'X N_$?B*Y^SV-MA55!NEN)#]V-%[L?\
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M/"7C'QJ?%'PW_9NL\R^&;G2(S;>+KY8O+BN+D,Q78F!^[VL#EP>&->X^/?\
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M\4?MQ>"OVF?V>/$O@BV^)WA#PU-X7O/#_C"WDDTW5[!Y7D&R2,[XI,R.,\#
M'/4-@_!/_@IQ\7/A=^VA\//A3^U3\"O#W@7Q+\2UGTWPCXU\+ZFNJ:9?W"#S
M'LVW+YL.0%XW$$LN1W'I'[=?_!+CQ5\>?VA-.^-'P;^-?BOX*?%BPTH:)<W$
M,0U/1]9LU?>D5Q92G9P2?F7KQQD!JY']GK_@D%\0M5_:J\'?&7]I3X[ZE\:O
M%'PW\Z3PGI-EHT6BZ+H\\J[6N?*C),DFW."W0X.3@ (LXW_@ZB8K_P $W/#6
M./\ BYOAW_T;+7Z4U\W?\%2O^"?$7_!2S]G'3?A_-XFE\*)I_B73_$7VV.T%
MR7-JSMY6TLOWMW7/&.E?2-( KRS]G7_DH7QE_P"QV7_TS:57J=>6?LZ_\E"^
M,O\ V.R_^F;2J /4Z\;_ &\/@[KWQV_9YG\/>&[>"YU1]8TJ\$<TPA7RX+^"
M:0[CQD(C$#N1BO9*R[GQMI-GX@32Y;^V34),!8"WS9()4'L"0"0#R<<5=*4H
M34X[K4BI%2BXRV9\^_M#_LU_$G]HO]IC1]7LO$MIX&\,_#N(7.@3M81:J^IZ
MC,I66=X'953RD.Q"<G+,1UJ']G;]F7XE_LX?M-ZYJMWXCM/'/A7XC1->:]<B
MRBTI]-U*(!8YDMT9E<2ID.5P=P!(/6OI4ZC MR(3*GF,C2!<]54@,?P)%3!P
M6QD9QG&>U;?6Y\GL]+6MM^N^^IE]6AS<^M[WW_I;:'@O[)WP'\2_"C]DC5_"
M>M6UO!K=W<:Q)%%'<+(A%Q-*T66''(=<^E?-'[/W[$7B;X6> _">GZS^SGI>
ML:]H4< N=77XA/")YHV#><(@=HY .W&.*_0Y[F-(]Q==N"P.>H')K/UGQII7
MA_3(+R\OH(+:Y($+DY\W@M\H')^4$\=@35PQM1.5E\3OU_1HF6$@U%](Z=/U
M1\S?\%0],NHO"_P]\1W=C+>^'?#NOQ7.LVR#>%C.WEAW'#+Z?-[UH_M7_%7X
M/?M!?LP:A!/XST&%&@%UI;K*#<6UP@S&!$/G&?ND8Z$U]$ZO<:3K/AR3[<UC
M=:5=PCS!-MDAFC?@9!X*G(_.O+U_8:^#.A:^NJGP5H45TS[E\QG,3-R>(RVP
M\ \8[=*\&OA*KG-T[-35G>_33H?J>1<5Y93PF$IX_P!K"IA)2E3E2Y=>:2E:
M2E:SNOB5[K1Q=CYQ_P"";,U_^T5\;7\9>*-5@O;_ ,!Z-#I&G6I/[W:RLOG$
M?[NX%N[-[5Z[^T/X ^).A_ME>&?B-X*\'V'B^PT[PO<:+<P3:S'I[I+)<>8"
M"X.1@>G>O:O"_P )_"&@>*IO$FD:+I=GJM_ JRWEM$(WFB(& <8&,*.W:NDN
MM0ALK=I9942-%WLQ/ 7U^E=>64Y82'++WGK??6__  #P^/,_HY_F7UK"P=.F
MHQ48:>Y;=*VC7,V[V3=]CY=_:E^#'Q!_:\_9AD:Z\'Q>#/B9H>J++H/V37DD
MEMXVVQS.MRJ@*'A>52G? ]JW?VK_ -FK56_9L\$>%_AEX?L;EO!'B#2M2M=+
M>[6TC>"T<NR^8W&X]SU)8FO=O$'C;2?"OD_VA?VUI]H!,>]OO*,9;V49&2>!
MGK6GYR8)W+A1D\]!7HK$SCRV6B=UO_7_  Y\4\/%MW>K5F?*?[1.E_&C]J;]
MG3QSX*U#X7:9X;FU735%C-_PD\-TMS,L\1\H@(-@*!CN/I[UA?LY?LV:G\./
MBKX9U _L\Z?X;DLI%CFUI/'LEZUFI0J\H@)(?_=]Z^Q8]0AEGDC65"\3!77/
MW21D#\13K:[BO(1)#)'+&>C(P8'\15+&24'3C%)/U_S_ #)^JQ<U-N[^7^1)
M1117&=05Y]XP^#EYXE^(/]JV^HP:=;3HD=V8(Y%N;B,*RF,G?Y9!#?>*;E['
MI7H-%1.$9JTCCQN H8N"IUU=)I[M:KT/.],^$>K#1=(TZ]U#26MM!N[>6T:U
MLFB>2.%77$F7(W'<.0 ,@\<UB:!^S%.O@_3=%U;4X+FVTN]ANXI+<3+)^[BD
M12"\C;&#.K K@ KTKU^BL_JU-[H\N?#&73<74A>RMJV]--'KKLON/,_ OP2U
MCX=S6+VFL:??-]G6VU"2]L2SS!9Y)=\>UQL8^8<CE<@'%9VC?LZZCI/AJ_TQ
M[[2KR&6Y%S;&:*X^1A.THR!*-I&[AH]I!&?:O7:*/JU.UK N%\N48P47:*:2
MYI.RDDGN^MM?/4QOA_X=N_"?A"RT^^OFU*ZMU(>X9<;LDD <DX ( R2<#DUL
MT45LDDK(]NC1C2IQI0VBDEUV\WJPHHHIFH4444 %%%% !1110 4444 %%%%
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MIDCM_EB =&.6)3RV Z$[SRO2KOAOX3ZCX:\3:':0E8='MUDGO1 [*DDD4KM
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; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
